Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closureInterim analysis planned ...

Phase III trial to assess the efficacy and safety of EscharEx® for debridement and facilitation of active wound closure Interim analysis planned after 65% of patients complete treatment, expected in ...

YAVNE, Israel, Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics ...

MediWound’s first drug, NexoBrid®, is an FDA- and EMA-approved orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need ...

Geneos Wealth Management Inc. raised its holdings in shares of Vericel Co. (NASDAQ:VCEL – Free Report) by 826.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities & ...

a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.

Vericel also holds an exclusive license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal ...

MediWound (MDWD) shares ended the last trading session 8.5% higher at $19.83. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This ...

Brown recluse bites may cause an area of dead skin that's called an eschar, which typically sloughs off and leaves an ulcer behind. Unlike black widow bites, brown recluse bites aren't painful ...